Tag Archives: Glembatumumab vedotin

Celldex’s ADC Glembatumumab-vedotin for Triple Negative Breast Cancer

Antibody drug conjugate Glembatumumab vedotin (GV) is in late phase 2 trials for patients with triple negative breast cancer (TNBC) – those whose tumors do not express estrogen, progesterone, or HER-2. Approximately 15% of breast cancer patients have TNBC; it is an important area of research for both researchers and clinicians alike because: Continue reading